Urological Research Foundation's home page
About the Urological Research Foundation
Prostate Cancer Questions & Answers
Quest Newsletter Articles
Media articles and interviews with Dr. Catalona
Books published by other authors
Dr. Catalona's journal articles from various publications
Dr. Catalona's genetic research for prostate cancer
Donate to the URF for prostate cancer research
View the New Patient Packet sent by Dr. Catalona
Links to other helpful prostate cancer websites
Contact the Urological Research Foundation
Dr. Catalona's Library Articles


ASSOCIATION BETWEEN GENETIC POLYMORPHISMS IN THE PROSTATE-SPECIFIC ANTIGEN GENE PROMOTER AND SERUM PROSTATE-SPECIFIC ANTIGEN LEVELS.

Cramer SD, Chang BL, Rao A, Hawkins GA, Zheng SL, Wade WN, Cooke RT, Thomas LN, Bleecker ER, Catalona WJ, Sterling DA, Meyers DA, Ohar J, Xu J.

BACKGROUND: Recent evidence suggests that genetic variation in the promoter of the prostate-specific antigen (PSA) gene may contribute to individual variation in serum PSA levels. However, polymorphisms associated with variations in PSA levels have not been identified.

METHODS: We used the polymerase chain reaction to amplify the promoter region of the PSA genes (nucleotide positions -3873 to -5749 with respect to the start of transcription) of 409 healthy white men at risk for lung disease. Polymerase chain reaction products were sequenced to identify polymorphisms in the PSA gene promoter and to genotype the men for common single nucleotide polymorphisms (SNPs) and were cloned into luciferase reporter constructs to assay PSA promoter activity in human LNCaP prostate cancer cells. Analysis of variance was used to test the association of polymorphism frequencies with mean serum PSA levels. All statistical tests were two-sided.

RESULTS: The -4643G/A SNP (G allele) had a 21.2% prevalence and was associated with increases in serum PSA levels (P =.017) and PSA promoter activity (P<.001). The -5412C/T SNP (C allele) had a 22.0% prevalence and was associated with an increase in serum PSA levels (P =.0015). The -5429T/G SNP (G allele) had a 23.0% prevalence, was associated with an increase in serum PSA levels (P =.021), and was in linkage disequilibrium with the -5412C/T SNP. The promoter activity of the -5412 C/-5429 G haplotype was higher than that of the -5412 T/-5429 T haplotype (P<.001).

CONCLUSIONS: Genetic variations in the PSA promoter are associated with serum PSA levels in men without prostatic disease. PSA promoter genotype information may help to refine models of PSA cutoff values.

INSTITUTION: Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA. scramer@wfubmc.edu


J Natl Cancer Inst. 2003 Jul 16;95(14):1044-53.


Home    |    About the URF   |    Q & A - Prostate Cancer   |    Quest Articles
Journal Articles   |    National Media   |    Suggested Reading   |    Genetic Research
Donations   |    New Patient Packet   |    Post-Op Advice   |    Helpful Links   |    Contact Us